Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?

Figure 1

Clinical course in the ECMO-supported COVID-19 patient. (a) Anticoagulant argatroban was administered throughout the provision of venovenous ECMO. Anticoagulation effect. (b) Time course of platelets and results of the ELISA test (ZYMUTEST^® HIA IgG). Anti-heparin/PF4 antibodies detected by optical density (OD) read on days 12, 14, and 20 were monitored by measuring activated partial thromboplastin time (aPTT) and thrombin time (TT). (c) Time course of fibrinogen, D-dimer, and C-reactive protein (CRP). (d) Undulating course of coagulation time (CT) in intrinsic (IN) and ecarin (ECA) tests in contrast to the relatively uniform course of aPTT measurement.

(a)

(b)

(c)

(d)